Key facts
- Aculys’s last known valuation is $247.5M (Feb 2025).
- It has raised $118.1M; the latest was Merger/Acquisition in Oct 2025.
- Status: Acquired/Merged (Operating Subsidiary).
- ·Watchlist + deal alerts for Aculys
- ·The full record, as it builds
Funding rounds
No funding rounds for Aculys are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aculys
Operator of a clinical-stage biopharmaceutical company intended to eliminate drug lag/drug loss in Japan and is working to resolve social issues related to neurological and psychiatric diseases. The company creates drugs that are aimed at helping patients who are suffering from debilitating neurologic diseases and specializes in central nervous system treatment, enabling patients to improve their quality of life.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2021
- Employees
- 15
- Website
- aculys.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Aculys doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aculys shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aculys in its N-PORT filings yet. We sweep new filings monthly.